Moderna, Inc.

This early-stage trial is testing an experimental mRNA vaccine called mRNA-1195 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). The study involves 482 healthy adults aged 18 to 55, some of whom have had EBV before and some who have not. Part…

This large phase 3 trial is testing an experimental mRNA vaccine (mRNA-1018-H5) designed to protect against H5N1 pandemic influenza. Around 4,000 healthy adults aged 18 and older will receive two doses of the vaccine or a placebo. Researchers will measure immune responses and mon…

This study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 84 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent CMV after stopping stand…

This study tests an experimental mRNA vaccine (mRNA-1982) designed to prevent Lyme disease, which is spread by tick bites. About 350 healthy adults aged 18 to 70 will receive either the vaccine or a placebo to check for safety and immune response. The goal is to find the best dos…

This early-stage trial is testing two mRNA vaccines in children aged 5 months to under 24 months. One vaccine targets RSV alone, and the other targets both RSV and hMPV. The main goals are to check safety and see how well the vaccines trigger an immune response. About 186 childre…

This large Phase 3 study is testing an mRNA vaccine called mRNA-1403 to prevent norovirus, a common cause of severe stomach upset and diarrhea. About 38,000 adults aged 18 and older will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent…

This study is testing an experimental mRNA vaccine called mRNA-1189 to see if it can safely prevent Epstein-Barr virus (EBV) infection in healthy people aged 10 to 30. EBV is a common virus that can cause mononucleosis and has been linked to some cancers. The vaccine is given as …

This study tests two updated mRNA COVID-19 vaccines (mRNA-1283 and mRNA-1273 variant formulation) in 30,000 healthy adults aged 50 to 64 who are not at high risk for severe COVID-19. The goal is to see if these vaccines prevent symptomatic COVID-19 compared to a placebo. Research…

This study tests two experimental mRNA vaccines, mRNA-1403 and mRNA-1405, designed to prevent norovirus, a common cause of severe vomiting and diarrhea. Around 1,400 healthy adults aged 18 to 80 will receive either a vaccine or a placebo. The main goals are to check safety and me…

This phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage trial tests an mRNA drug called mRNA-3745 in 15 adults and children with glycogen storage disease type 1a (GSD1a), a rare genetic condition that causes dangerously low blood sugar. The drug is given by IV infusion and aims to help the body produce a missing enzym…

This study tracks over 4,200 people in South Korea who received a SPIKEVAX COVID-19 vaccine to see if any side effects occur over time. Participants are aged 12 or older depending on the vaccine version. The goal is to gather real-world safety data, not to test if the vaccine wor…

This early-stage trial is testing the safety of a new experimental drug called mRNA-0184 in 52 healthy adults. Participants receive one or more injections of the drug, and researchers monitor for side effects and how the drug moves through the body. Since this is a Phase 1 study,…